This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, R.-H. Articles by McCormick, F. Search for Related Content PubMed PubMed Citation Articles by Chen, R.-H. Articles by McCormick, F.

Selective Targeting to the Hyperactive ß-Catenin/T-Cell Factor Pathway in Colon Cancer Cells¹

Cancer Research Institute, University of California, San Francisco, San Francisco, California 94115

Many colon cancers suffer mutations in either the adenomatous polyposis coli or ß-catenin genes that lead to stabilization of ß-catenin and activation of downstream T-cell factor (Tcf) target genes. We have developed a novel approach targeting colon cancer cells based on their aberrant ß-catenin/Tcf signaling pathway. A recombinant adenovirus, in which an apoptosis gene fadd is under the control of the promoter containing Tcf-responsive elements, selectively and efficiently kills colon cancer cells in which the ß-catenin/Tcf pathway is hyperactivated. Our data therefore provide a conceptual proof that aberrantly activated Wnt/ß-catenin/Tcf pathways can be used to selectively target colon cancers.

This article has been cited by other articles:

				L. Lamant, A. d. Reynies, M.-M. Duplantier, D. S. Rickman, F. Sabourdy, S. Giuriato, L. Brugieres, P. Gaulard, E. Espinos, and G. Delsol Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes Blood, March 1, 2007; 109(5): 2156 - 2164. [Abstract] [Full Text] [PDF]

				H. Dvory-Sobol, E. Sagiv, D. Kazanov, A. Ben-Ze'ev, and N. Arber Targeting the active {beta}-catenin pathway to treat cancer cells. Mol. Cancer Ther., November 1, 2006; 5(11): 2861 - 2871. [Abstract] [Full Text] [PDF]

				T. Kuroda, S. D. Rabkin, and R. L. Martuza Effective Treatment of Tumors with Strong {beta}-Catenin/T-Cell Factor Activity by Transcriptionally Targeted Oncolytic Herpes Simplex Virus Vector. Cancer Res., October 15, 2006; 66(20): 10127 - 10135. [Abstract] [Full Text] [PDF]

				D. J. Mulholland, S. Dedhar, G. A. Coetzee, and C. C. Nelson Interaction of Nuclear Receptors with the Wnt/{beta}-Catenin/Tcf Signaling Axis: Wnt You Like to Know? Endocr. Rev., December 1, 2005; 26(7): 898 - 915. [Abstract] [Full Text] [PDF]

				M. Bordonaro, D. L. Lazarova, and A. C. Sartorelli Pharmacological and genetic modulation of Wnt-targeted Cre-Lox-mediated gene expression in colorectal cancer cells Nucleic Acids Res., May 11, 2004; 32(8): 2660 - 2674. [Abstract] [Full Text] [PDF]

				J.-H. Xiao, C. Ghosn, C. Hinchman, C. Forbes, J. Wang, N. Snider, A. Cordrey, Y. Zhao, and R. A. S. Chandraratna Adenomatous Polyposis Coli (APC)-independent Regulation of {beta}-Catenin Degradation via a Retinoid X Receptor-mediated Pathway J. Biol. Chem., August 8, 2003; 278(32): 29954 - 29962. [Abstract] [Full Text] [PDF]

				A. de la Taille, M. A. Rubin, M.-W. Chen, F. Vacherot, S. G.-D. de Medina, M. Burchardt, R. Buttyan, and D. Chopin {beta}-Catenin-related Anomalies in Apoptosis-resistant and Hormone-refractory Prostate Cancer Cells Clin. Cancer Res., May 1, 2003; 9(5): 1801 - 1807. [Abstract] [Full Text] [PDF]